asthma
AZ’s Fasenra approved in Europe as an add-on for severe eosinophilic asthma
January 11, 2018Research and Development AstraZeneca, European Commission, Fasenra, MedImmune, asthma, pharma
AstraZeneca and its biologics R&D unit MedImmune have announced that their drug Fasenra (benralizumab) has received approval from the European …
AstraZeneca’s Fasenra scores US approval in severe asthma
November 15, 2017Research and Development, Sales and Marketing AstraZeneca, Fasenra, MedImmune, asthma
AstraZeneca and MedImmune, the company’s biologics research and development division, have revealed the decision by the FDA to approve Fasenra …
AstraZeneca asthma therapy tralokinumab flops at Phase 3
November 1, 2017Research and Development AstraZeneca, MedImmune, asthma, pharma
AstraZeneca and MedImmune, the company’s global biologics research and development arm, have announced new Phase 3 data revealing that tralokinumab …
Amgen and AstraZeneca’s experimental drug cuts asthma exacerbations by up to 71%
September 7, 2017Research and Development Amgen, AstraZeneca, MedImmune, asthma, pharma, pharmaceutical, tezepelumab
An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …
Asthma drugs reduce Parkinson’s risk by 50%, decade-long study finds
September 5, 2017Manufacturing and Production, Research and Development Parkinson's, Parkinson's disease, asthma, pharma, pharmaceuticals, salbutamol
A study from the Department of Global Public Health and Primary Care at the University of Bergen (UiB) in Norway …
Teva asthma treatment scores NICE approval
July 20, 2017Sales and Marketing Teva, asthma, biotech, cinqaero, drugs, healthcare, pharma, pharmaceuticals
NICE has reached a decision in its final appraisal determination of Teva’s Cinqaero (reslizumab), recommending the drug’s use as an …
Severe asthma patients require more support, Novartis study suggests
June 19, 2017Research and Development, Sales and Marketing Novartis, asthma
A new study from Novartis has indicated that patients suffering from severe asthma still do not get adequate support to …
Strong showing for AZ asthma drug, but diabetes treatment flops
May 23, 2017Manufacturing and Production, Research and Development AstraZeneca, asthma, diabetes
AstraZeneca has been mulling over mixed news this week after both its severe asthma treatment and diabetes therapy saw varying …
Off-patent cancer drug holds promise for severe asthma treatment
May 18, 2017Research and Development asthma, imatinib
Researchers from Brigham and Women’s Hospital and Harvard Medical School have conducted a small-scale study into the prospect of using …
AZ asthma drug falls short in Phase 3 study
May 10, 2017Research and Development AstraZeneca, asthma, tralokinumab
AstraZeneca and its global biologics research and development arm MedImmune have announced that asthma treatment tralokinumab has failed to achieve …
Teva launches competitors to GSK’s Advair inhaler
April 21, 2017Medical Communications, Sales and Marketing Advair, AirDuo, GSK, Teva, asthma
GSK has been anticipating competition to its Advair for two years and Teva has announced that it will be the …
Asthma drugs may have alternative function as pneumonia treatment
March 1, 2017Research and Development asthma, influenza, pneumonia
Researchers from the University of Virginia School of Medicine have discovered that two drugs commonly used to treat asthma, Accolate …
NICE recommends GSK’s “first-in-class” asthma drug
November 30, 2016Sales and Marketing GSK, NICE, Nucala, asthma
NICE has announced its recommendation of GSK’s “first-in-class” biologic Nucala (mepolizumab) as an extra option for the treatment of adults …
Teva team up with IBM to tackle two challenges facing the pharma industry
October 27, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cloud Computing, Teva Pharmaceutical, asthma, ibm
Teva Pharmaceuticals and IBM have announced a partnership that will use IBM Watson Health Cloud with the aim of finding …
AstraZeneca forced to abandon Phase II trial
October 12, 2016Research and Development AstraZeneca, Synairgen, asthma, cold, common cold
Synairgen, a respiratory drug discovery and development company, has developed a drug, AZD9412, alongside AstraZeneca to treat and prevent severe …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
